Flexible Access to AJICAP™ Technology
AJICAP™ offers flexible access to conjugation and linker technologies through licensing and technology transfer models tailored to customer needs. Programs may begin with feasibility evaluation and sample preparation, while broader development activities are typically supported through licensing. AJICAP™ provides process development, analytical support, and technology transfer expertise, enabling efficient integration into customer workflows.
Commercial Licensing Model
AJICAP™ licensing is not a fixed protocol. Our chemistry team works with licensees to adapt the process for specific antibodies, payloads, equipment configurations, and regulatory requirements.
Manufacturing Process Rights
Full AJICAP™ process rights for cGMP clinical and commercial manufacturing
Technology Transfer
Complete tech transfer package – process descriptions
Process Optimization
Ongoing technical support and process optimization access
Partner Support
Manufacture at your facility or designated partner CDMO
Integrating AJICAP™ into Your ADC Therapy
AJICAP™ supports the integration of conjugation and linker technologies into customer development programs through a structured technology transfer and process adaptation approach. We work with customers to map the manufacturing process and identify development activities required for implementation. Our structured approach helps reduce development risk and supports efficient integration into manufacturing workflows.
Customized to Remove Constraints
AJICAP™ is designed to provide flexibility across a wide range of bioconjugate development programs. Depending on the conjugation strategy, the technology is compatible with diverse antibody formats, linker-payload designs, and customer-specific payloads.
Ready to move forward?
Multiple licensing models, full tech transfer support, from first evaluation through commercial manufacturing.
Resources
Frequently Asked Questions
How is intellectual property protected?
AJICAP™ core technology and related intellectual property are owned by Ajinomoto. Product-specific intellectual property remains with the customer. Confidentiality and intellectual property considerations are addressed through appropriate contractual agreements and technology transfer processes.
What is the typical transfer timeline?
Technology transfer timelines vary depending on program scope, process complexity, manufacturing strategy, and development stage. Transfer activities are planned on a project-specific basis to support efficient implementation and manufacturing readiness.
What support do you provide after transfer?
AJICAP core technology and related intellectual property are owned by Ajinomoto Group. Product-specific development and associated intellectual property remain with the customer. Confidentiality and intellectual property considerations are addressed through appropriate contractual agreements and technology transfer processes.
Can the process scale with my program?
Yes. AJICAP™ technologies can be applied from early-stage evaluation through clinical and commercial manufacturing. Process development and technology transfer support are available to facilitate scale-up, while manufacturing can be performed by qualified AJICAP™ partner CDMOs or customer-selected manufacturing partners. This flexible approach enables efficient progression throughout the product lifecycle.
How do you ensure regulatory compliance?
AJICAP™ core technology and related intellectual property are owned by the Ajinomoto Group. Product-specific development and associated intellectual property remain with the customer. Confidentiality and intellectual property considerations are addressed through appropriate contractual agreements and technology transfer processes.
Which tech transfer platforms are best for CDMOs?
Technology transfer timelines vary depending on program scope, process complexity, manufacturing strategy, and development stage. Transfer activities are planned on a project-specific basis to support efficient implementation and manufacturing readiness.